Activation of the serine proteinase system in chronic kidney rejection

Transplantation

Volumn 65, Issue 12, 1998, Pages 1628-1634

  Tang, Wen Hao ^a   Friess, Helmut ^a   Di Mola, Fabio F ^a   Schilling, Martin ^a   Maurer, Christoph ^a   Graber, Hans U ^a   Dervenis, Christos ^a   Zimmermann, Arthur ^b   Büchler, Markus W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR;

ALLOGRAFT; ARTICLE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT REJECTION; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

AGED; BLOTTING, NORTHERN; CHRONIC DISEASE; ENZYME ACTIVATION; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032572292     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199806270-00015     Document Type: Article

References (25)

1. Cecka JM. Outcome statistics of renal transplants with an emphasis on long-term survival. Clin Transplant 1994; 8: 324.
2. Schweizer EJ, Matas AJ, Gillingham KJ, et al. Causes of renal allograft loss: progress in the 80's, challenge in the 90's. Ann Surg 1991; 214: 679.
3. Horvath LZ, Friess H, Schilling M, et al. Altered expression of transforming growth factor-β in chronic renal rejection. Kidney Int 1996; 50: 489.
4. Shihab FS, Yamamoto T, Nast CC, et al. Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995; 6: 286.
5. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992; 42(6): 1462.
6. Shihab FS, Tanner AM, Shao Y, Weffer MI. Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50(6): 1904.
7. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 1986; 163: 1037.
8. Ikegami M, Ishii T, Uemura T, et al. Urinary tissue type plasminogen activator and plasminogen activator inhibitor in renal transplant patients. Transplant Proc 1992; 24: 1547.
9. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor-beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105: 1846.
10. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993; 53: 2704.
11. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994; 158: 398.
12. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surface: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1993; 103: 2411.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
14. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992; 90: 1352.
15. Deflorin J, Friess H, Schobinger S, et al. Overexpression of the epidermal growth factor receptor family in gastric cancer suggests a role in tumor pathogenesis. Dig Surg 1997; 14: 252.
16. Yamanaka Y, Friess H, Büchler M, et al. Synthesis and expression of transforming growth factor-beta 1, beta 2, and beta 3 in the endocrine and exocrine pancreas. Diabetes 1993; 42: 746.
17. Friess H, Yamanaka Y, Büchler M, et al. Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis. Am J Pathol 1994; 144: 117.
18. Friess H, Yamanaka Y, Büchler M, et al. A subgroup of patients with chronic pancreatitis overexpress the c-erbB-2 protooncogene. Ann Surg 1994; 220: 183.
19. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75: 388.
20. Brown R, Jarvis K, Hyland K. Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal Biochem 1989; 180: 136.
21. Stoppelli MP, Tacchetti C, Cubellis MV, et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675.
22. Bajpai A, Baker JB. Cryptic urokinase binding sites on human foreskin fibroblasts. Biochem Biophys Res Commun 1985; 133: 475.
23. Chapman HA, Stone OL, Vavrin Z. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro: characterization of a plasminogen activator and its role in matrix degradation. J Clin Invest 1984; 73: 806.
24. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor beta by growing cultures of osteoblast-like cells. J Cell Physiol 1993; 157: 528.
25. Martin TJ, Allan EH, Fukumoto S. The plasminogen activator system in bone remodeling. Growth Regul 1993; 3: 209.